Evidence map›Paper›PMID 42642529›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026

Effects of intranasal antihistaminic and corticosteroid therapies on olfactory dysfunction in adults with perennial allergic rhinitis: a prospective comparative study.

Ayşe Enise Göker, Elif Aksungur, Cem Çelik, Uğur Uygan, Gülpembe Bozkurt, Ayça Başkadem Yılmazer, Maide Hacer Alagöz

Abstract read
PubMed Publisher
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ayşe Enise GökerDepartment of Otorhinolaryngology, University of Health Sciences, Prof. Dr. Cemil Taşcıoğlu City Hospital, İstanbul, Türkiye.
Elif AksungurDepartment of Otorhinolaryngology, Pendik Yüzyıl Hospital, İstanbul, Türkiye.
Cem ÇelikDepartment of Otorhinolaryngology, Gaziantep City Hospital, Gaziantep, Türkiye. ceemcelik1@gmail.com.ORCID http://orcid.org/0000-0002-8538-2081
Uğur UyganDepartment of Otorhinolaryngology, Hakkari State Hospital, Hakkari, Türkiye.
Gülpembe BozkurtDepartment of Otorhinolaryngology, University of Health Sciences, Prof. Dr. Cemil Taşcıoğlu City Hospital, İstanbul, Türkiye.
Ayça Başkadem YılmazerDepartment of Otorhinolaryngology, University of Health Sciences, Prof. Dr. Cemil Taşcıoğlu City Hospital, İstanbul, Türkiye.
Maide Hacer AlagözDepartment of Biochemistry, University of Health Sciences, Kartal Dr. Lütfi Kırdar City Hospital, İstanbul, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo compare the effects of commonly used intranasal therapies on olfactory dysfunction in adults with perennial allergic rhinitis using objective psychophysical testing.

methodsThis prospective study included 90 adults with perennial allergic rhinitis and objectively confirmed hyposmia. Patients were allocated into three treatment groups: intranasal azelastine monotherapy, intranasal azelastine plus mometasone furoate combination therapy, and intranasal mometasone furoate monotherapy. Treatments were administered for one month. Olfactory function was assessed before and after treatment using the Sniffin' Sticks test (threshold, discrimination, identification, and composite TDI score). Nasal obstruction was evaluated using the Nasal Obstruction Symptom Evaluation (NOSE) scale. Between-group comparisons of treatment-related change scores and supportive within-group analyses were performed using non-parametric statistical tests.

resultsNinety patients were included, with 30 patients in each treatment group. The mean ages were 29.43 ± 10.58 years in the azelastine group, 29.13 ± 8.79 years in the azelastine plus mometasone furoate group, and 29.90 ± 6.33 years in the mometasone furoate group. Baseline TDI scores were 29.10 ± 1.45, 28.37 ± 2.83, and 27.70 ± 2.34, respectively. Mean ΔTDI was - 3.33 ± 4.14 in the azelastine group, 9.13 ± 4.35 in the combination group, and 11.90 ± 3.82 in the mometasone furoate group, with a significant between-group difference (p < 0.001).

conclusionIn adults with perennial allergic rhinitis and objectively confirmed hyposmia, intranasal corticosteroid-containing regimens were associated with greater improvement in olfactory function than azelastine monotherapy. These findings suggest that intranasal corticosteroid-containing regimens may be preferable when olfactory dysfunction accompanies perennial allergic rhinitis. However, given the non-randomized and open-label design of the study, the results should be interpreted with caution.

Indexed as

Allergic rhinitisHyposmiaIntranasal antihistaminesIntranasal corticosteroidsOlfactory dysfunctionSniffin’ Sticks

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.